Company intelligence / Profile preview
Tarn Biosciences
East Lansing, Michigan, USAlegacy.www.sbir.gov ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Preclinical
01
Overview
Developing HC2099 series of MmpL3 inhibitors with promising in vitro activity (100 nM EC50). Working on formulation studies, PK studies, and in vivo efficacy studies in murine TB infection models.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Michigan State University (MSU)Spartan Innovations
Beyond the preview
Go deeper on Tarn Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tarn Biosciences.